Zika Virus: Current Treatment Landscape, Prevention, and Research Pipeline

There is no specific antiviral therapy or licensed vaccine for Zika virus (ZIKV) infection. Management is entirely supportive.

Symptomatic Treatment

  • Rest, hydration.
  • Acetaminophen for fever, arthralgia, headache (avoid NSAIDs until dengue excluded due to bleeding risk).
  • Antihistamines for pruritic rash.

Special Populations

  • Pregnant women: Serial ultrasounds (fetal anatomy, growth, neuroimaging), amniocentesis for ZIKV RNA if indicated; multidisciplinary counseling.
  • Guillain‑Barré syndrome: IVIG or plasma exchange per standard protocols.

Prevention (Primary Strategy)

  • Mosquito bite avoidance: EPA‑registered repellents (DEET, picaridin, IR3535, oil of lemon eucalyptus), permethrin‑treated clothing, window screens, A/C.
  • Sexual transmission prevention: Condoms or abstinence during pregnancy if partner traveled to endemic area (CDC: 3 months for men, 2 months for women).
  • Vector control: Source reduction (standing water), larvicides, adulticides, Wolbachia‑infected mosquito releases, genetically modified mosquitoes (field trials).

Research Pipeline

  • Vaccines: DNA (VRC5283), mRNA (Moderna mRNA‑1893), purified inactivated (TAK‑426), viral vector (Ad26.ZIKV.001)—Phase 1/2 completed; efficacy trials hampered by declining incidence.
  • Antivirals: Sofosbuvir (repurposed), BCX4430, peptide inhibitors targeting NS2B‑NS3 protease—preclinical/early clinical.
  • Monoclonal antibodies: ZIKV‑117, Z004, Z006—potent neutralization in animal models.

WHO and CDC maintain Zika as a Public Health Emergency of International Concern (PHEIC) legacy priority; surveillance continues in endemic regions.

Viral Infections - Related Articles